- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06938126
Effects of L-Arginine and Citrulline Malate Supplementation on Sport Performance in Physically Active Men (ReachSci)
April 14, 2025 updated by: Leonidas Petridis, Hungarian University of Sports Science
Acute Effects of Combined Supplementation of L-Arginine and Citrulline Malate on Aerobic, Anaerobic, and CrossFit® Exercise Performance
In this randomized, double-blind, placebo-controlled trial we investigated the effects of combined L-arginine (Arg) and citrulline-malate (CM) supplementation on aerobic, anaerobic, and high-intensity interval training in healthy, physically active men.
46 healthy, physically active men were divided into three distinct exercise protocol groups: CrossFit group, the Wingate Anaerobic Test group, and the Harvard Step Test group.
The CrossFit performance assessment involved the "Cindy" workout, a high-intensity protocol composed of bodyweight exercises organized in a set sequence: 5 pull-ups, 10 push-ups, and 15 squats.
Participants were instructed to perform as many rounds as possible within 20 minutes.
The Wingate Anaerobic test involved a 30-second all-out cycling test on a bike ergometer, while the Harvard Step Test The Harvard Step Test was conducted using a 51 cm high platform, with participants stepping at a rate of 30 steps per minute (one second up, one second down) for five minutes or until exhaustion.
Each participant attended three separate laboratory sessions.
The initial session served for familiarization with the test protocol to minimize learning effects.
In the second and the third sessions, participants attended two measurement sessions, conducted in randomized order and under double-blind conditions, where they received either the dietary supplementation or a placebo.
Each participant acted as their control, allowing for within-subject comparisons.
Study Overview
Status
Completed
Conditions
Detailed Description
Consumption of dietary supplements is a common strategy among athletes aiming to optimize recovery after training or competitions and enhance athletic performance.
Amino acids L-arginine (Arg) and L-citrulline (Cit) are two of the most widely used supplements in recent times.
Their use as nutritional supplements or dietary supplements to improve health and athletic performance has increased dramatically, as both Arg and Cit are essential for the body's synthesis of nitric oxide (NO) and elimination of waste products such as lactate during physical activity.
Because it functions as an endogenous precursor to Arg, the primary substrate of nitric oxide, Cit, a non-protein, non-essential amino acid, has attracted a lot of attention lately for its potential to improve exercise performance.
Commonly, citrulline is consumed as citrulline malate (CM), which is a mixture of Cit and malic acid in ratios ranging from 1:1 to 2:1.
The combined intake of Arg and CM could potentially enhance athletic performance more effectively than using either supplement alone.
This synergistic benefit is attributed to Cit's role in synthesizing additional Arg, which in turn elevates NO production, enhancing blood flow and possibly reducing muscle fatigue.
Supporting this hypothesis, mixed supplementation of Arg and CM was examined in a previous study and significant increases in both force exertion and fatigue resistance during a 10-minute high-intensity cycling test was found.
However, while initial evidence suggests potential ergogenic benefits of combined Arg and CM supplementation, further research is needed to confirm these effects across various exercise modalities.
The aim of this study was to investigate the acute effects of combined Arg and CM supplementation on anaerobic performance, aerobic performance, or both through high-intensity interval training (i.e.
CrossFit) outcomes in healthy, physically active men.
Based on existing research, it was hypothesized that the supplementation would enhance performance by achieving higher peak power in the anaerobic protocol and CrossFit in the CrossFit training protocol, where rapid energy production and resistance to fatigue are critical.
Study Type
Interventional
Enrollment (Actual)
46
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Budapest, Hungary, 1124
- Hungaria University of Sports Science
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- being healthy, physically active with no history of injuries or illnesses at the time of measurement or within the preceding six months
Exclusion Criteria:
- consumption of any dietary supplements in the last six months to avoid confounding effects
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Supplementation
Supplementation of L-Arginine and Citrulline-malate as a liquid
|
L-Arginine and Citrulline Malate supplementation was consumed as a liquid one single time to examine the acute effects on sport performance
|
|
Placebo Comparator: Placebo
Consumption of a placebo liquid
|
Consumption of placebo as a liquid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mechanical Power
Time Frame: Day 1 and Day 2
|
Maximal and mean mechanical power was assessed during the Wingate Anaerobic Test under both conditions (supplementation and placebo).
|
Day 1 and Day 2
|
|
Fitness Score
Time Frame: Day 1 and Day 2
|
During the CrossFit exercise and the Harvard Step Test the primare measure of performance was a Fitness Score, which was calculated from the rounds completed for the CrossFit exercise and from the time duration and heart rate for the Harvard Step Test.
|
Day 1 and Day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heart Rate
Time Frame: Day 1 and Day 2
|
Maximal and mean heart rate was measured for all three exercise protolcols: The Wingate Anaerobic Test, The CrossFit Test, and the Harvard Step Test.
|
Day 1 and Day 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 1, 2023
Primary Completion (Actual)
May 15, 2024
Study Completion (Actual)
September 30, 2024
Study Registration Dates
First Submitted
April 7, 2025
First Submitted That Met QC Criteria
April 14, 2025
First Posted (Actual)
April 22, 2025
Study Record Updates
Last Update Posted (Actual)
April 22, 2025
Last Update Submitted That Met QC Criteria
April 14, 2025
Last Verified
April 1, 2025
More Information
Terms related to this study
Other Study ID Numbers
- TE-KEB/22/2023
- HungarianUSportsScience (Other Identifier: Hungarian University of Sports Science)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All individual data the are included in the study and support the statistical analysis
IPD Sharing Time Frame
from April 1, 2025 to December 31, 2025
IPD Sharing Access Criteria
Data are available by the corresponding author
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Study Data/Documents
-
Individual Participant Data Set
Information identifier: TE-KEB/22/2023Information comments: For more information please email to: petridis.leonidas@tf.hu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.